EPS for Allena Pharmaceuticals, Inc. (ALNA) Expected At $-0.48 on December, 13

November 8, 2018 - By Ricky Cave

On December, 13 is awaited Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)’s earnings report, according to Zacks. The EPS diference is $3.01 or 86.25 % up from last years number. Previous year: $-3.49; Analysts forcast: $-0.48. After $-0.42 EPS was published last quarter, analysts now see negative EPS growth of 14.29 % for Allena Pharmaceuticals, Inc.. The stock increased 8.58% or $0.68 during the last trading session, reaching $8.61.Allena Pharmaceuticals, Inc. is after having 0.00% since November 9, 2017. ALNA has 58,311 volume or 16.51% up from normal. ALNA underperformed by 15.62% the S&P500.

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States.The company has $178.68 million market cap. The company's lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.Currently it has negative earnings. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases.

More recent Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) news were brought out by Globenewswire.com, Nasdaq.com and Nasdaq.com. The first one has “Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November” as a title and was brought out on November 06, 2018. The next is “Allena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the …” on October 18, 2018. And last was brought out on November 07, 2018, called “Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update”.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.